Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
22.54
-0.13 (-0.57%)
At close: Oct 2, 2026, 4:00 PM EDT
22.93
+0.39 (1.73%)
After-hours: Oct 2, 2026, 7:32 PM EDT
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
440.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| ARS Pharmaceuticals | 116.93M |
| Assembly Biosciences | 74.85M |
| Prothena Corporation | 54.53M |
| Ovid Therapeutics | 1.58M |
TECX News
- 3 days ago - Tectonic Therapeutic Transcript: Stifel 2026 Virtual Cardiometabolic Forum - Transcripts
- 4 days ago - Tectonic Therapeutic announces results from Phase 1a trial of TX2100 - TheFly
- 4 days ago - Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) - GlobeNewsWire
- 4 weeks ago - Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 1 month ago - Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 1 month ago - Tectonic Therapeutic Quarterly report: Q2 2026 - Filings
- 1 month ago - Tectonic Therapeutic Earnings release: Q2 2026 - Filings
- 2 months ago - Tectonic Therapeutic Slides: Investor presentation - Filings